PMID- 33142288
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1421-9875 (Electronic)
IS  - 0257-2753 (Linking)
VI  - 39
IP  - 4
DP  - 2021
TI  - Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with 
      Chronic Constipation: A Propensity Score-Matched Analysis.
PG  - 341-350
LID - 10.1159/000512745 [doi]
AB  - INTRODUCTION: Elobixibat is a new laxative, but its efficacy and adverse events 
      (AEs) are insufficiently examined compared with those of other laxatives. Hence, 
      by propensity score (PS) matching, we compared the effects and AEs between 
      elobixibat and lubiprostone. METHODS: We retrospectively analyzed 1,887 Japanese 
      patients with chronic constipation (CC) treated at our hospital between October 
      2013 and April 2020. Enrolled patients were divided into three treatment groups, 
      namely, elobixibat (10 mg daily) (E10 group, n = 293), lubiprostone (24 mug daily) 
      (L24 group, n = 772), and lubiprostone (48 mug daily) (L48 group, n = 822), as 
      their first treatment. We then investigated the changes on the weekly average 
      number of spontaneous bowel movements, stool consistency scores (SCSs), and AEs 
      starting from the baseline until the end of the 2-week treatment. To adjust for 
      patients' background, we performed one-to-one nearest neighbor matching without 
      replacement between elobixibat- and lubiprostone-treated patients according to 
      the individual estimated PSs. RESULTS: After treatment, for SCSs, both the L24 
      and L48 groups significantly improved compared with the E10 group (p < 0.05), but 
      their stools were soft (Bristol Stool Form Scale: 4.8). Notably, the E10 group 
      had less frequent AEs than the L24 group (26 [9.0%] vs. 43 [14.8%], p = 0.03). 
      Particularly, nausea was significantly less in the E10 group than that in the L48 
      group (2 [0.7%] vs. 7 [2.4%], p = 0.01). CONCLUSION: Elobixibat is a beneficial 
      drug for patients with mildly symptomatic CC and is safe to use, given its few 
      AEs.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - Eguchi, Takaaki
AU  - Eguchi T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan, egugu0515@yahoo.co.jp.
FAU - Yoshizaki, Tetsuya
AU  - Yoshizaki T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Ikeoka, Seitaro
AU  - Ikeoka S
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Takagi, Megumi
AU  - Takagi M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Fujinami, Maho
AU  - Fujinami M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Matsuda, Tatsuya
AU  - Matsuda T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Yamaguchi, Tsubasa
AU  - Yamaguchi T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Nonaka, Takahiro
AU  - Nonaka T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Amioka, Shohei
AU  - Amioka S
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Katayama, Norio
AU  - Katayama N
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Inoue, Kazuki
AU  - Inoue K
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Matsumoto, Masanori
AU  - Matsumoto M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Momose, Kenji
AU  - Momose K
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Sako, Tomoya
AU  - Sako T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Noda, Mari
AU  - Noda M
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Morisawa, Toshiyuki
AU  - Morisawa T
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
FAU - Okada, Akihiko
AU  - Okada A
AD  - Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, 
      Osaka, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201103
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Dipeptides)
RN  - 0 (Laxatives)
RN  - 0 (Thiazepines)
RN  - 7662KG2R6K (Lubiprostone)
RN  - 865UEK4EJC (elobixibat)
SB  - IM
MH  - Chronic Disease
MH  - Constipation/*drug therapy
MH  - Defecation/drug effects
MH  - Dipeptides/*therapeutic use
MH  - Female
MH  - Humans
MH  - Laxatives/*therapeutic use
MH  - Lubiprostone/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Thiazepines/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse event
OT  - Constipation
OT  - Elobixibat
OT  - Lubiprostone
OT  - Propensity score
EDAT- 2020/11/04 06:00
MHDA- 2021/07/17 06:00
CRDT- 2020/11/03 20:15
PHST- 2020/08/12 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
PHST- 2020/11/03 20:15 [entrez]
AID - 000512745 [pii]
AID - 10.1159/000512745 [doi]
PST - ppublish
SO  - Dig Dis. 2021;39(4):341-350. doi: 10.1159/000512745. Epub 2020 Nov 3.